SCHEMBL881216

SCHEMBL881216

Cn1nc(C(F)(F)F)c(C(=O)NC2(c3ccc(C(=O)O)cc3)CC2)c1Oc1ccc(C(F)(F)F)cc1

nearest known ligand 0.81

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 20/20 0.81
PTGER2 P43116 3/20 0.51
PTGDR Q13258 2/20 0.46
TBXA2R P21731 1/20 0.46
PTGER1 P34995 1/20 0.46
PTGFR P43088 1/20 0.46
PTGER3 P43115 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15250014 0.93 PTGER4 (0.70) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL881504 0.92 PTGER4 (0.74) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL10122339 0.90 PTGER4 (1.00) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL15249918 0.89 PTGER4 (0.82) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL881197 0.88 PTGER4 (0.76) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL881421 0.86 PTGER4 (0.74) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL15249882 0.85 PTGER4 (0.83) PTGER4PTGER2PTGDRTBXA2RPTGER1
SCHEMBL15250013 0.85 PTGER4 (0.64) PTGER4PTGER2PTGDR
SCHEMBL15249969 0.82 PTGER4 (0.87) PTGER4PTGER2
SCHEMBL15250015 0.81 PTGER4 (0.71) PTGER4PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619182-B1 PHARMACEUTICAL COMPOSITION EISAI R&D MAN CO LTD (JP) 2016-11-09 EP disclosed
EP-3061751-A1 PHARMACEUTICAL COMPOSITION Eisai R&D Management Co., Ltd. (JP) 2016-08-31 EP disclosed
US-9000024-B2 Pharmaceutical composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-07 US disclosed
US-9000024-B2 Pharmaceutical composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-07 US disclosed
US-20140155452-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-05 US disclosed
US-20140155452-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-05 US disclosed
US-20130237578-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-12 US disclosed
US-20130237578-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-12 US disclosed
WO-2012039972-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155452-A1 PHARMACEUTICAL COMPOSITION CYP3A5, CYP2C19, CYP3A7 PTGER4 147/4885PTGER2 131/4885PTGDR 599/4885
US-20130237578-A1 PHARMACEUTICAL COMPOSITION CYP3A5, CYP2C19, CYP3A7 PTGER4 147/4885PTGER2 131/4885PTGDR 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.